Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03700320
Recruitment Status : Active, not recruiting
First Posted : October 9, 2018
Last Update Posted : March 25, 2019
Sponsor:
Information provided by (Responsible Party):
Allergan

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 22, 2020
Estimated Study Completion Date : November 9, 2020